⛔ Huestis Safety & Tolerability Trial (2026) – The Fine Print

This industry‑funded trial (Johnson Foods) is often cited as proof of safety. But the data tell a different story:

• 116 participants, but 6 were withdrawn early because of adverse events – including one with “seizure‑like activity” after a single dose.
• Liver enzyme elevations (ALT/AST) forced termination in multiple participants; one case met study criteria for stopping dosing.
• Severe adverse events included vasovagal syncope, gastroenteritis, and one case of uterine hemorrhage – the latter never before reported and unresolved at study end.
• Dose‑dependent increase in TEAEs – at the highest dose, 98% of participants had mild events (nausea, dizziness, vomiting), and 2% moderate – in a controlled clinical setting.

⛔ Human Pharmacokinetics (2024) – The Metabolite Problem

This study reveals why daily use is dangerous: the active metabolite 7‑OH‑mitragynine accumulates in the body.

• 7‑OH is 13‑fold more potent at the mu‑opioid receptor than mitragynine, and it is produced internally – meaning users are effectively dosing themselves with a stronger opioid every day.
• Steady state takes 8–9 days, and the half‑life is extremely long (40–60 hours), leading to accumulation and increasing withdrawal risk.
• Concentration ratios of 7‑OH/mitragynine were higher after single doses than after repeated doses, suggesting the body tries to limit exposure – a sign of toxicity.

⛔ FDA-Registered Clinical Study (NCT06072170)

This study enrolled recreational polydrug users with opioid experience – exactly the population susceptible to abuse. The results confirm what we already knew:

• At the highest dose (12 g), drug liking scores were significantly elevated compared to placebo (mean 68.7 vs 50.2).
• "High" scores skyrocketed at the top dose (mean 46.3 vs 0.4 for placebo), with a p‑value <0.001 – clear evidence of psychoactive effect.
• Adverse events were dose‑dependent: 5 of 6 subjects in the 8 g and 10 g cohorts reported events (somnolence, nausea, vomiting).
• The study population was not representative of the general public – they were chosen because they seek out drug effects.

⛔ What the Advocates Won't Tell You

• These studies used pure, tested kratom powder – not the gas station products laced with heavy metals, salmonella, or synthetic adulterants. Real‑world kratom is far more dangerous.
• All participants were healthy, medically screened adults. No one with liver disease, heart conditions, or on medications – the typical consumer is excluded.
• Duration was only 15 days. No data on long‑term addiction, organ damage, or withdrawal severity after months of use.
• Industry funding (Johnson Foods) creates a clear conflict of interest. The authors are paid consultants of the company selling kratom.
• The very existence of these studies proves nothing about safety in the real world. They are being weaponized to lobby against regulation while the real victims – families dealing with addiction and death – are ignored.